SCHEMBL4219902

SCHEMBL4219902

Cc1c(C(=O)OC(C)(C)C)ccc2c1CCC2NC(=O)c1cc(C(=O)NCc2ccc(F)c(F)c2)nc2c(C(=O)O)cnn12

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 6/20 0.72
ADAMTS4 O75173 2/20 0.72
MMP3 P08254 2/20 0.72
MMP8 P22894 1/20 0.53
MMP12 P39900 1/20 0.53
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
MAPK1 P28482 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
TP53 P04637 3/20 0.35
EPHX2 P34913 1/20 0.34
NR1H4 Q96RI1 1/20 0.34
MET P08581 1/20 0.34
POLB P06746 1/20 0.34
KLKB1 P03952 1/20 0.33
CACNA1G O43497 1/20 0.33
CACNA1H O95180 1/20 0.33
CACNA1I Q9P0X4 1/20 0.33
CYP1A1 P04798 1/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4219896 1.00 MMP13 (0.72) MMP13ADAMTS4MMP3MMP8MMP12
SCHEMBL5427943 0.95 MMP13 (0.65) MMP13ADAMTS4MMP3MMP8MMP12
SCHEMBL5428072 0.95 MMP13 (0.65) MMP13ADAMTS4MMP3MMP8MMP12
SCHEMBL5428067 0.95 MMP13 (0.65) MMP13ADAMTS4MMP3MMP8MMP12
SCHEMBL10209510 0.95 ADAMTS4 (0.65) MMP13ADAMTS4MMP3MMP8MMP12
SCHEMBL5431521 0.95 MMP13 (0.65) MMP13ADAMTS4MMP3MMP8MMP12
SCHEMBL4227668 0.93 MMP13 (0.73) MMP13ADAMTS4MMP3MMP8MMP12
SCHEMBL4227666 0.93 MMP13 (0.73) MMP13ADAMTS4MMP3MMP8MMP12
SCHEMBL10209436 0.93 MMP13 (0.63) MMP13ADAMTS4MMP3MMP8MMP12
SCHEMBL10167987 0.93 MMP13 (0.65) MMP13ADAMTS4MMP3MMP8MMP12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2038284-A2 HETEROBICYLIC METALLOPROTEASE INHIBITORS Alantos Pharmaceuticals, Inc. (US) 2009-03-25 EP disclosed
WO-2007139860-A2 HETEROBICYLIC METALLOPROTEASE INHIBITORS ALANTOS PHARMACEUTICALS, INC. (US) 2007-12-06 WO disclosed
US-20070155737-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155737-A1 Heterobicyclic metalloprotease inhibitors ADAMTS4, ADAMTS1, ADAMTS5 MMP13 38/4885ADAMTS4 1/4885MMP3 33/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.